Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Revefenacin

FDA-approved product (solution, inhalation), marketed as Yupelri.

Registered studies
20
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Revefenacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Chronic obstructive pulmonary disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinergics
FDA pharmacologic class
Anticholinergic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

20registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Revefenacin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Revefenacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

    NCT07721922 · start 2026-09-01

    Registered record
    Registry ID
    NCT07721922
    Conditions
    COPD Exacerbation
    Interventions
    Revefenacin; formoterol fumarate; Placebo (Sterile Normal Saline); Albuterol sulfate; Ipratropium Bromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2028-09-01
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD Exacerbation
    InterventionRevefenacin; formoterol fumarate; Placebo (Sterile Normal Saline); Albuterol sulfate +1 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

    NCT07133880 · start 2023-12-05

    Registered record
    Registry ID
    NCT07133880
    Conditions
    COPD (Chronic Obstructive Pulmonary Disease)
    Interventions
    umeclidinium 62.5 µg and vilanterol 25 µg; Revefenacin 175 µg, Formoterol 20 µg; Placebo ( Revefenacin and Formoterol ); Placebo DPI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-12-05
    Completion
    2026-12-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD (Chronic Obstructive Pulmonary Disease)
    Interventionumeclidinium 62.5 µg and vilanterol 25 µg; Revefenacin 175 µg, Formoterol 20 µg; Placebo ( Revefenacin and Formoterol ); Placebo DPI
    PhasePhase 4
    Registry statusRecruiting

  • Phase 4 COPD and Suboptimal Inspiratory Flow Rate

    NCT05165485 · start 2022-01-07

    Registered record
    Registry ID
    NCT05165485
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    Revefenacin; Tiotropium; Revefenacin Placebo; Tiotropium Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-01-07
    Completion
    2023-11-20
    Enrolment
    404

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    InterventionRevefenacin; Tiotropium; Revefenacin Placebo; Tiotropium Placebo
    PhasePhase 4
    Registry statusCompleted

  • Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

    NCT05046795 · start 2021-11-10

    Registered record
    Registry ID
    NCT05046795
    Conditions
    COPD
    Interventions
    Revefenacin 175 mcg in 3 ML Inhalation Solution; Placebo inhalation solution QD
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-11-10
    Completion
    2023-07-26
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionRevefenacin 175 mcg in 3 ML Inhalation Solution; Placebo inhalation solution QD
    PhasePhase 3
    Registry statusCompleted

  • Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution

    NCT05207111 · start 2021-09-23

    Registered record
    Registry ID
    NCT05207111
    Conditions
    Healthy Volunteers Bioavailability Study
    Interventions
    Revefenacin Inhalation Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-23
    Completion
    2021-09-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers Bioavailability Study
    InterventionRevefenacin Inhalation Solution
    PhasePhase 1
    Registry statusCompleted

  • Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

    NCT04655170 · start 2020-12-09

    Registered record
    Registry ID
    NCT04655170
    Conditions
    COPD Exacerbation
    Interventions
    Revefenacin (YUPELRI) & Formoterol (Perforomist); Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-12-09
    Completion
    2023-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD Exacerbation
    InterventionRevefenacin (YUPELRI) & Formoterol (Perforomist); Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
    PhasePhase 4
    Registry statusCompleted

  • Revefenacin in Acute Respiratory Insufficiency in COPD

    NCT04315558 · start 2020-11-01

    Registered record
    Registry ID
    NCT04315558
    Conditions
    COPD; Acute Respiratory Failure
    Interventions
    Revefenacin Inhalation Solution [Yupelri]; Ipratropium Bromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-01
    Completion
    2025-01-01
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD; Acute Respiratory Failure
    InterventionRevefenacin Inhalation Solution [Yupelri]; Ipratropium Bromide
    PhasePhase 2
    Registry statusCompleted

  • A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

    NCT03573817 · start 2018-05-31

    Registered record
    Registry ID
    NCT03573817
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    Revefenacin; Placebo; Formoterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-31
    Completion
    2018-09-25
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionRevefenacin; Placebo; Formoterol
    PhasePhase 3
    Registry statusCompleted

  • Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

    NCT03095456 · start 2017-03-27

    Registered record
    Registry ID
    NCT03095456
    Conditions
    Chronic Obstructive Pulmonary Disease, COPD; Low Peak Inspiratory Flow Rate (PIFR)
    Interventions
    Revefenacin; Spiriva Handihaler®; Placebo for Revefenacin; Placebo for Spiriva Handihaler®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-27
    Completion
    2017-11-25
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease, COPD; Low Peak Inspiratory Flow Rate (PIFR)
    InterventionRevefenacin; Spiriva Handihaler®; Placebo for Revefenacin; Placebo for Spiriva Handihaler®
    PhasePhase 3
    Registry statusCompleted

  • Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

    NCT02820311 · start 2016-05

    Registered record
    Registry ID
    NCT02820311
    Conditions
    Cardiac Repolarization in Healthy Subjects
    Interventions
    TD-4208 175 mcg; TD-4208 700 mcg; Placebo for TD-4208; Moxifloxacin 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05
    Completion
    2016-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Repolarization in Healthy Subjects
    InterventionTD-4208 175 mcg; TD-4208 700 mcg; Placebo for TD-4208; Moxifloxacin 400 mg
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

    NCT02578082 · start 2015-12

    Registered record
    Registry ID
    NCT02578082
    Conditions
    Renal Impairment
    Interventions
    TD-4208
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionTD-4208
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

    NCT02581592 · start 2015-11

    Registered record
    Registry ID
    NCT02581592
    Conditions
    Hepatic Impairment
    Interventions
    TD-4208
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11
    Completion
    2016-04
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionTD-4208
    PhasePhase 1
    Registry statusCompleted

  • Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

    NCT02459080 · start 2015-09

    Registered record
    Registry ID
    NCT02459080
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    TD-4208; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2016-09
    Enrolment
    619

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionTD-4208; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

    NCT02512510 · start 2015-09

    Registered record
    Registry ID
    NCT02512510
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    TD-4208; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2016-09
    Enrolment
    611

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionTD-4208; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

    NCT02518139 · start 2015-09

    Registered record
    Registry ID
    NCT02518139
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    TD-4208; Tiotropium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2017-06
    Enrolment
    1,060

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionTD-4208; Tiotropium
    PhasePhase 3
    Registry statusCompleted